Lexeo Therapeutics' (LXEO) PKP2-ACM Program Under the Radar - Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).

The analyst commented, "While there is significant investor attention on the lead program in Friedreich's ataxia, we believe the PKP2-ACM program is still under the radar; this upcoming data in January may change that narrative. Today's event helped to clarify how amenable this patient population could be to a gene therapy approach, especially as it relates to the impact of traumatic cardiac events that could motivate patients to get a potential one-time approach. Even if we conservatively assumed just 5,000 patients (a single-digit percentage of the market size) received this therapy, that is cumulative potential sales of $10B alone."

For an analyst ratings summary and ratings history on Lexeo Therapeutics click here. For more ratings news on Lexeo Therapeutics click here.

Shares of Lexeo Therapeutics closed at $9.51 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
• JPMorgan Downgrades Indorama Ventures PCL (IVL:TB) to Neutral
• Spruce Biosciences (SPRB) PT Lowered to $144 at Citizens on Higher OpEx, Net Loss